Biotech Business - October 24, 2017
AdaptVac reaches proof of concept
ExpreS2ion’s new joint venture, AdaptVac, reaches proof of concept in advanced animal models (POCA) for AV-001, its novel vaccine treatment against breast cancer tumours. The scientific results that form the basis of the proof of concept in animal models show a strong therapeutic effect on par with leading treatments on the market. The data will […]
Drug Development Pharma - October 2, 2017
EMA Validation for Camurus
The company’s marketing authorization application (MAA) for the investigational, weekly and monthly CAM2038 buprenorphine depots for the treatment of opioid dependence has been fully validated by the European Medicines Agency. The application, submitted on 26 July 2017, is now under assessment by the Committee for Human Medicinal Products (CHMP). “The validation of the MAA for CAM2038 […]
Drug Development Pharma - September 14, 2017
Turning science fiction into true science
NLSDays 2017 started off with a super session with the title “Gene therapy in regenerative medicine” and both challenges and possibilities were discussed. Dr Sven Kili, Head of Cell and Gene Therapy Development at GSK, gave the audience a comprehensive overview of the progress and developments within the field of gene therapy, including the facts that […]
Drug Development Pharma - September 7, 2017
Positive results from Photocure
Photocure reports that a prospective controlled study investigating the introduction of Blue Light Cystoscopy (BLC) with Hexvix at first presentation in patients with non-muscle invasive bladder cancer (NMIBC) in routine clinical practice has been published in the World Journal of Urology. The overall recurrence rates at 3 years were significantly less in patients who received […]
Drug Development Pharma - August 23, 2017
Lynparza receives additional approval in the US
AstraZeneca and Merck & Co announced that the US Food and Drug Administration (FDA) has granted approval for the PARP inhibitor, Lynparza (olaparib). The approval is as follows: New use of Lynparza as a maintenance treatment for recurrent, epithelial ovarian, fallopian tube or primary peritoneal adult cancer who are in response to platinum-based chemotherapy, regardless of BRCA status New […]
Collaboration - August 11, 2017
Lundbeck collaborates on study between genetics and psychiatric disorders
H. Lundbeck joins personal genetics company 23andMe and think tank the Milken Institute in a large new study to increase the understanding of the underlying causes of Major Depressive Disorder (MDD/unipolar depression) and Bipolar Depression. Further, the study will explore how these disorders and brain functions such as attention and decision-making are related to genetics. […]
